Cytovale Inc., a San Francisco-based medical technology company, has picked up $15 million in financing to advance its technology that enables the early detection of sepsis in the emergency department. Specifically, the company raised $7.4 million in an extension of series B equity financing, co-led by existing investors Breakout Ventures and Blackhorn Ventures. Western Technology Investment also participated, providing a venture debt facility to the company.

Brian MacDonald's pursuit of an approved hepcidin therapy at Merganser Biotech Inc. didn't quite pan out, but that didn't stop him from taking up Atlas Venture's offer to try it once again on a different tack.